Lido Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Lido Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,256	Closed	-$298K	–	585
2019 Q1	$298K	Buy	+4,256	New	+$316K	0.02%	395

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lido Advisors's GHDX Position: Q2 2019 in Review

Lido Advisors sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 4,256 shares — an estimated $298K sold.

Lido Advisors first reported a position in GHDX in Q1 2019 and held it in 1 quarter. The position peaked at $298K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

Lido Advisors reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
Lido Advisors sold 4,256 Genomic Health, Inc. shares in Q2 2019, an estimated $298K.
Lido Advisors first reported a position in Genomic Health, Inc. in Q1 2019 and held it in 1 quarter.
Lido Advisors's Genomic Health, Inc. position peaked at $298K in Q1 2019.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Lido Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.